Freedom from Technical and Licensing Challenges in Genome Editing
Bayspair's Scarless Editing technology makes it easy to achieve “freely rewriting the genome sequence”—something that was difficult with conventional genome editing techniques. Furthermore, Bayspair has independently developed a nuclease system to replace CRISPR/Cas9. Bayspair leverages these technologies to free customers from technical challenges and licensing issues, accelerating research, development, and business utilizing genome editing.
Genome-edited iPS cell bank
An unprecedented lineup of genome-edited cells including reporter cell lines and cells with disease-associated SNP, which are difficult to produce with conventional technologies, are available. Collaboration-friendly with a simple license.
Genome editing service
Affordable genome service using Bayspair's Scarless Editing technology, which dramatically reduces the difficulty and cost of genome editing. We undertake genome editing of any design with a high success rate and on a contingency fee basis.
Genome editing technology licensing
Bayspair's genome editing technology can be licensed for all purposes, including commercial and clinical applications, providing partners and collaborators with a flexible business scheme.